Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026
Compass Therapeutics published positive Phase 2/3 COMPANION-002 results for tovecimig plus paclitaxel in advanced biliary tract cancer in the Journal of Clinical Oncology, with an ESMO 2026 oral presentation. The study met its primary endpoint with an ORR of 18.0% vs 5.3% for paclitaxel alone, and its key secondary endpoint with median PFS of 4.7 vs 2.6 months (HR=0.44), a 56% reduction in risk of progression or death. The intent-to-treat OS analysis was confounded by 54% crossover; a post hoc Two-Stage Estimation showed an OS hazard ratio of 0.85 that was not statistically significant (p=0.53).
Key figures
- Drug Name
- tovecimig
- Phase Of Trial
- Phase 2/3
- Median dor
- 4.9 months
- Dcr control
- 36.8%
- Orr control
- 5.3%
- Dcr combination
- 62.2%
- Orr combination
- 18.0%
- Pfs hazard ratio
- 0.44
- Median pfs control
- 2.6 months
- Pfs risk reduction
- 56%
- Patients randomized
- 168
- Median pfs combination
- 4.7 months
- Btc patients us annually
- 26500
- Os p value crossover adjusted
- 0.53
- Os hazard ratio crossover adjusted
- 0.85
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.